The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer.
W. Zhong
No relevant relationships to disclose
X. Yang
No relevant relationships to disclose
R. Liao
No relevant relationships to disclose
Q. Nie
No relevant relationships to disclose
S. Dong
No relevant relationships to disclose
J. Su
No relevant relationships to disclose
X. Zhang
No relevant relationships to disclose
Q. Zhou
No relevant relationships to disclose
J. Yang
No relevant relationships to disclose
Y. L. Wu
No relevant relationships to disclose